Stock NVSEF NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis AG OTC Markets

Equities

NVSEF

CH0012005267

Pharmaceuticals

Delayed OTC Markets
Other stock markets
 07:00:07 13/05/2024 pm IST 		5-day change 1st Jan Change
102 USD +0.01% Intraday chart for Novartis AG +7.11% +2.00%
13/05 Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales DJ
10/05 Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,14,715 2,15,682 1,96,476 1,94,400 2,07,226 2,09,220 - -
Enterprise Value (EV) 1 2,30,615 2,40,182 2,04,667 2,03,434 2,19,237 2,21,659 2,20,562 2,14,802
P/E ratio 30.4 x 26.7 x 8.2 x 28.3 x 14.1 x 20 x 17.2 x 15.8 x
Yield 3.19% 3.56% 3.83% 3.87% 3.79% 3.52% 3.66% 3.84%
Capitalization / Revenue 4.53 x 4.43 x 3.81 x 3.85 x 4.56 x 4.27 x 4.12 x 4.08 x
EV / Revenue 4.86 x 4.94 x 3.96 x 4.02 x 4.82 x 4.53 x 4.34 x 4.19 x
EV / EBITDA 14.6 x 14.3 x 11.2 x 10.9 x 12.2 x 11.5 x 10.7 x 10.2 x
EV / FCF 17.9 x 20.5 x 15.4 x 17 x 16.6 x 16 x 14.4 x 13.3 x
FCF Yield 5.58% 4.87% 6.49% 5.87% 6.01% 6.26% 6.95% 7.51%
Price to Book 3.87 x 3.78 x 2.9 x 3.23 x 4.42 x 4.59 x 4.59 x 4.29 x
Nbr of stocks (in thousands) 22,64,608 22,74,506 22,37,092 21,50,980 20,55,460 20,40,406 - -
Reference price 2 94.81 94.83 87.83 90.38 100.8 102.5 102.5 102.5
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 47,445 48,659 51,626 50,545 45,440 48,957 50,791 51,311
EBITDA 1 15,809 16,845 18,246 18,613 17,937 19,244 20,658 21,066
EBIT 1 14,112 15,416 16,588 16,665 16,372 18,039 19,225 19,586
Operating Margin 29.74% 31.68% 32.13% 32.97% 36.03% 36.85% 37.85% 38.17%
Earnings before Tax (EBT) 1 8,940 9,878 26,137 8,371 9,123 13,202 14,628 15,181
Net income 1 7,147 8,072 24,021 6,955 14,854 10,423 11,918 12,805
Net margin 15.06% 16.59% 46.53% 13.76% 32.69% 21.29% 23.47% 24.96%
EPS 2 3.120 3.550 10.71 3.190 7.150 5.117 5.970 6.496
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,866 15,320 16,129
FCF margin 27.14% 24.03% 25.73% 23.63% 29% 28.32% 30.16% 31.43%
FCF Conversion (EBITDA) 81.44% 69.4% 72.79% 64.18% 73.47% 72.06% 74.16% 76.57%
FCF Conversion (Net income) 180.15% 144.83% 55.29% 171.75% 88.72% 133.04% 128.54% 125.96%
Dividend per Share 2 3.025 3.375 3.360 3.500 3.823 3.611 3.749 3.937
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13,229 12,531 12,781 12,543 12,690 12,953 13,622 11,782 11,423 11,829 12,253 12,477 12,766 11,905 12,155
EBITDA 4,274 4,407 4,989 4,783 4,473 - 4,668 - 4,224 - - - - - -
EBIT 1 3,819 4,083 4,270 4,282 4,030 4,413 4,668 4,405 3,821 4,537 4,588 4,697 4,542 4,790 4,895
Operating Margin 28.87% 32.58% 33.41% 34.14% 31.76% 34.07% 34.27% 37.39% 33.45% 38.35% 37.45% 37.64% 35.58% 40.24% 40.27%
Earnings before Tax (EBT) 1 16,951 2,669 2,042 1,919 1,741 2,740 2,769 1,552 2,377 3,129 3,856 3,879 3,664 - -
Net income 1 16,308 2,222 1,695 1,575 1,466 2,293 2,316 1,513 8,480 2,688 2,777 2,814 2,515 - -
Net margin 123.27% 17.73% 13.26% 12.56% 11.55% 17.7% 17% 12.84% 74.24% 22.72% 22.66% 22.55% 19.7% - -
EPS 2 7.290 1.000 0.7700 0.7300 0.6900 1.090 1.110 0.7300 4.140 1.310 1.358 1.386 1.252 - -
Dividend per Share 2 3.360 - - - 3.500 - - - 3.823 - 0.9539 0.9539 0.9539 1.019 1.019
Announcement Date 02/02/22 26/04/22 19/07/22 25/10/22 01/02/23 25/04/23 18/07/23 24/10/23 31/01/24 23/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,900 24,500 8,191 9,034 12,011 12,439 11,342 5,582
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.006 x 1.454 x 0.4489 x 0.4854 x 0.6696 x 0.6464 x 0.5491 x 0.265 x
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,866 15,320 16,129
ROE (net income / shareholders' equity) 17.5% 23.5% 22.7% 21% 25.4% 32.4% 38% 37.4%
ROA (Net income/ Total Assets) 8.89% 6.45% 10.9% 10.7% 12.4% 10.7% 12.8% 14.2%
Assets 1 80,393 1,25,215 2,21,201 64,915 1,20,082 96,977 93,123 90,092
Book Value Per Share 2 24.50 25.10 30.30 28.00 22.80 22.30 22.30 23.90
Cash Flow per Share 2 5.880 5.950 6.670 6.480 6.910 7.790 8.430 8.720
Capex 1 2,257 1,275 1,378 1,198 1,060 1,195 1,267 1,318
Capex / Sales 4.76% 2.62% 2.67% 2.37% 2.33% 2.44% 2.49% 2.57%
Announcement Date 29/01/20 26/01/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.5 USD
Average target price
108.5 USD
Spread / Average Target
+5.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.99% 68TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 59TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.78% 36TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.74% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+3.19% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 20TCr
AMGEN INC. Stock Amgen Inc.
+7.37% 17TCr
PFIZER, INC. Stock Pfizer, Inc.
-1.88% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. NVSEF Stock
  5. Financials Novartis AG
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW